Special Drug Use Investigation of Nexavar (Unresectable or Advanced Renal Cell Carcinoma: Early Access Program)
Phase of Trial: Phase IV
Latest Information Update: 08 Jun 2018
At a glance
- Drugs Sorafenib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- Sponsors Bayer
- 05 Apr 2012 Actual patient number added 117 according to ClinicalTrials.gov.
- 05 Apr 2012 Actual end date (September 2011) added as reported by ClinicalTrials.gov.
- 05 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.